Nanjing Leads Biolabs Co (FRA:0DX) Ending Cash Position: €0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:0DX Nanjing Leads Biolabs Co Ltd FRA:0DX
19 GF Score
Price €7.15
! 1 Warning Sign
View Full Analysis

What is Nanjing Leads Biolabs Co Ending Cash Position?

Nanjing Leads Biolabs Co FRA:0DX -3.38% 19 Ending Cash Position is €0.00 Mil as of Dec. 2025. GuruFocus rates FRA:0DX with a GF Score™ of 19/100. The stock has 1 warning sign investors should review.

Nanjing Leads Biolabs Co's Ending Cash Position for the quarter that ended in Dec. 2025 was €0.00 Mil.

Nanjing Leads Biolabs Co's annual Ending Cash Position increased from Dec. 2023 (€31.79 Mil) to Dec. 2024 (€48.87 Mil) and increased from Dec. 2024 (€48.87 Mil) to Dec. 2025 (€148.07 Mil).

Nanjing Leads Biolabs Co Ending Cash Position Related Terms

Nanjing Leads Biolabs Co Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Nanjing Leads Biolabs Co's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanjing Leads Biolabs Co Ending Cash Position Chart

Nanjing Leads Biolabs Co Annual Data
Trend Dec23 Dec24 Dec25
Ending Cash Position
31.79 48.87 148.07

Nanjing Leads Biolabs Co Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
Ending Cash Position 0.00 0.00 0.00 0.00 0.00
FRA:0DX
19GF Score
Nanjing Leads Biolabs Co Ltd FRA:0DX
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nanjing Leads Biolabs Co Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Nanjing Leads Biolabs Co's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=45.172+102.895
=148.07

Nanjing Leads Biolabs Co's Ending Cash Position for the quarter that ended in Dec. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0+0
=0.00

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of €0.00 Mil mean?
Nanjing Leads Biolabs Co (FRA:0DX) has a Ending Cash Position of €0.00 Mil as of Dec. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Nanjing Leads Biolabs Co and its competitors.
Is Nanjing Leads Biolabs Co's Ending Cash Position too high?
Nanjing Leads Biolabs Co's current Ending Cash Position is €0.00 Mil. Overall, Nanjing Leads Biolabs Co has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Nanjing Leads Biolabs Co's Ending Cash Position compare to VRTX and REGN?
Nanjing Leads Biolabs Co's Ending Cash Position of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Nanjing Leads Biolabs Co and its competitors. Nanjing Leads Biolabs Co's current Ending Cash Position is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanjing Leads Biolabs Co stock overvalued right now?
Nanjing Leads Biolabs Co (FRA:0DX) has a current Ending Cash Position of €0.00 Mil. The current Ending Cash Position is €0.00 Mil. Nanjing Leads Biolabs Co's overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Nanjing Leads Biolabs Co (FRA:0DX), the current Ending Cash Position is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nanjing Leads Biolabs Co Business Description

Other Exchanges 09887:Hong Kong
Address Jialingjiang Street, 18E, Floor 8, Building 03, Jiangsu Province, Nanjing, CHN, 210019
Nanjing Leads Biolabs Co Ltd is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of new therapies in oncology, autoimmune, and other severe diseases. The Group uses its science-driven R&D approach and three proprietary technology platforms: X-body (4-1BB Engager), LeadsBody (CD3 T Cell Engager), and TOPiKinectics (ADC), for its multi-modal, differentiated pipeline in oncology and autoimmune diseases. It has approximately fourteen drug candidates across oncology and autoimmune diseases. Among these, one core product (LBL-024, a pivotal-stage PD-L1 and 4-1BB dual-targeting bispecific antibody) is being evaluated in several cancer indications and across various Proof-of-Concept (POC) studies. The Group generates maximum revenue from the USA.
19GF Score

Get the complete analysis for FRA:0DX

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.15
Price